Lonza to double production of Covid-19 vaccine at Swiss plant
Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort to boost the global supply of doses.
This content was published on
2 minutes
swissinfo.ch/SRF/gw
Español
es
Lonza duplicará la producción de la vacuna COVID-19 en su planta suiza
The new production lines will be added gradually to three existing lines and be fully operational by early 2022, Lonza said on Thursday. The two companies signed a ten-year contract in 2020 that enables Lonza to make a drug substance for the mRNA vaccine at its plant for the global market outside the United States.
In a separate press release, Moderna said it planned to increase the overall supply to up to three billion doses by 2022. The firm calculates there will be greater demand for its vaccine as the need for booster shots is likely to grow starting next year.
The announcement comes as Lonza struggles to recruit enough workers to join its Visp plant. Biotech specialists are currently in high demand worldwide as a result of the pandemic, Swiss public television, SRF, reported, adding that the interior ministry is now actively helping Lonza to find specialists from inside the federal administration and universities, including the federal technology institutes ETH Zurich and the EPFL in Lausanne.
Lonza has reportedly recruited temporary staff from food giant Nestlé with help from the Swiss government. Moderna has blamed projected delays in shipments of the vaccine to markets such as the UK and Canada on production bottlenecks, according to Reuters.
First large-scale alpine solar plant approved in Switzerland
This content was published on
The approval was met with satisfaction by the project's organisers, but it also brings with it a certain amount of pressure.
Medieval squirrels may have ‘helped spread leprosy’
This content was published on
An examination of squirrel remains in the United Kingdom has opened up interesting questions and possibilities in terms of the history of the disease.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
Swiss firm Lonza to help produce anti-Covid nasal spray in the US
This content was published on
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine.
Switzerland mulls future European coordination on medical supplies
This content was published on
“The pandemic has shown us that we are very dependent, maybe too much so, on other markets,” Swiss President Guy Parmelin has said.
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.